Famciclovir (FAMVIRρ)

Infectious Diseases in Obstetrics and Gynecology

Volumn 5, Issue 1, 1997, Pages 3-7

  Sacks, Stephen L ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Viridae Clinical Sciences Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 DEOXYPENCICLOVIR DIPROPIONATE; ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; PENCICLOVIR; PLACEBO; VALACICLOVIR;

ANTIVIRAL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG COST; GENITAL HERPES; GENITAL TRACT INFECTION; HEADACHE; HEPATITIS B VIRUS; HERPES ZOSTER; HUMAN; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS INHIBITION;

EID: 0030664331     PISSN: 10647449     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-0997(1997)5:1<3::aid-idog3>3.0.co;2-%23     Document Type: Conference Paper

References (31)

1. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL: Selection of an oral prodrug (BRL 42810; Famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 33:1765-1773, 1989.
2. Vere Hodge RA, Cheng Y-C: The mode of action of penciclovir. Antiviral Chem Chemother 4:13-24, 1993.
3. Perry CM, Wagstaff AJ. Famciclovir: A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 50:396-415, 1995.
4. Pue MA, Benet LZ: Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 4:47-55, 1993.
5. 14C-famciclovir to healthy subjects. Xenobiotica 24:357-368, 1994.
6. Famvir® Product Brochure. SmithKline Beecham Pharmaceuticals.
7. Weller S, Blum R, Doucette M, et al.: Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54:595-605, 1993.
8. Vere Hodge RA: Famciclovir and penciclovir: The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 4:67-84, 1993.
9. Gnann Jr JW: New antivirals with activity against varicella-zoster virus. Ann Neurol 34:569-72, 1994.
10. Winton CF, Fowles SE, Vere Hodge RA, et al.: Assay of famciclovir and its metabolites, including the antiherpes agent penciclovir, in plasma and urine of rats, dog, and man. In Reid E, Wilson ID (eds): Analysis of Drugs and Metabolites. Cambridge: Royal Soc Chemistry, pp 163-71, 1990.
11. Fowles SE, Pue MA, Pierce D, et al.: Pharmacokinetics of penciclovir in healthy elderly subjects following a single oral administration of 750 mg famciclovir [abstract]. Br J Clin Pharmacol 34:450P, Nov. 1992.
12. Cirelli R, Herne K, McCrary M, Lee P, Tyring SK: Famciclovir: Review of clinical efficacy and safety. Antiviral Res 29:141-151, 1996.
13. Boike SC, Pue MA, Freed MI, et al.: Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin Pharmacol Ther 55:418-26, Apr. 1994.
14. Boike SC, Pue M, Audet PR, et al.: Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. J Clin Pharmacol 34:199-207, 1994.
15. Fowles SE, Fairless AJ, Pierce DM, et al.: A further study of the effect of food on the bioavailability and pharmacokinetics of penciclovir after oral administration of famciclovir [abstract]. Br J Clin Pharmacol 32:657P, Nov. 1991.
16. Fowles SE, Pierce DM, Prince WT, et al.: Effect of food on bioavailability and pharmacokinetics of penciclovir, a novel antiherpes agent, following oral adminstration of the pro-drug, famciclovir [abstract]. Br J Clin Pharmacol 29:620P-1P, May 1990.
17. Pratt SK, Standring-Cox R, Writer D, et al.: Penciclovir pharmacokinetics in fed and fasted subjects following oral famciclovir in relation to in-vitro antiviral activity [abstract]. Proc 6th International Congress for Infectious Diseases (ICID). April 26-30, 1994.
18. Saltzman R, Jurewicz R, Boon R: Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 38:2454-2457, 1994.
19. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD, for the Canadian Famciclovir Study Group: Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: A randomized, double-blind multicenter trial. JAMA 276:44-49, 1996.
20. Sacks SL, Bishop AM, Fox R, et al.: A double-blind, placebo (PLB)-controlled trial of the effect of chronically administered oral famciclovir (FCV; BRL42810) on sperm production in men with recurrent genital herpes (RGH) infection [abstract]. Antiviral Res 23:72, 1994.
21. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S: In vitro activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother 38:719-723, 1994.
22. Tsiquaye KN, Slomka MJ, Maung M: Famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol 42:306-310, 1994.
23. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, Jones T, Rea T, Boon R, Saltzman R, and the Collaborative Famciclovir Herpes Zoster Study Group: Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and posherpetic neuralgia. Ann Intern Med 123:89-96, 1995.
24. Degreef H. and the Famciclovir Herpes Zoster Clinical Study Group: Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 4:241-246, 1994.
25. Sacks SL, Martel AY, Aoki FY, Shafran SD, St.-Pierre C, Lassonde M, and the Canadian Cooperative Study Group: Early, Clinic-Initiated Treatment of Recurrent Genital Herpes Using Oral Famciclovir: Results of a Canadian, Multicentre Study. Clinical Research Meeting, American Federation of Clinical Research 1994, Baltimore, Maryland (abstract).
26. Mertz GJ, Loveless MO, Kraus SJ, Tyring SK, Fowler SL, and the Collaborative Famciclovir Genital Herpes Research Group: Famciclovir for Suppression of Recurrent Genital Herpes. Interscience Conference on Antimicrobial Agents and Chemotherapy 1995, 11:H3 (abstract).
27. Diaz-Mitoma F, Sibbald RG, Shafran SD, and the Collaborative Famciclovir Genital Herpes Suppression Group: Famciclovir suppression of recurrent genital herpes. (abstract). Interscience Conference on Antimicrobial Agents and Chemotherapy 1996, New Orleans, LA
28. Main J, Brown JL, Karayiannis P, et al.: A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B infection. J Hepatol 21:S32, 1994.
29. Angus P, Richards M, Bowden S, Ireton J, Jones R, Locarnini S: Succesful treatment of post liver transplant recurrent hepatitis B. Presented at 34th Interscience Conf. Antimicrobial Agents and Chemotherapy (IC-CAC), Oct. 94, Orlando, FL.
30. Angus P, Neuhaus P, Manns MP, and the Famciclovir Liver Transplant Group: An open study to assess the effect of famciclovir on hepatitis B replication in patients who have received an orthotopic liver transplant. Presented at Liver Transplantation for Chronic Viral Hepatitis, Mar. 1995, Reston VA.
31. Boker KHW, Ringe B, Froger M, Picelmayr R, Manns MP: Prostaglandin E plus famciclovir: A new concept for the treatment of severe hepatitis B after liver transplantation. Transplanation 57:1706-1708, 1994.